Could prevention of infantile spasms have been possible in a historical cohort of 31 tuberous sclerosis patients?

Raili Riikonen1

  • 1University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, Postal Address: Yliopistonranta 1, FI-70110, Kuopio, Finland.

Insights

Preventing epilepsy in infants with tuberous sclerosis complex (TSC) is challenging. Early diagnosis of TSC is crucial for potential preventive treatment, but often delayed, hindering intervention effectiveness.

Area of Science:

  • Neurology
  • Genetics
  • Pediatrics

Background:

  • Tuberous sclerosis complex (TSC) is a genetic disorder.
  • Infantile spasms (IS) are common in TSC patients.
  • Preventing epilepsy in TSC infants is a key clinical goal.

Purpose of the Study:

  • To evaluate the feasibility of preventing epilepsy in infants with TSC.
  • To identify obstacles to early diagnosis and intervention.

Main Methods:

  • Retrospective chart review of 31 TSC patients with IS.
  • Analysis of clinical history, early development, TSC signs, seizure onset, EEG, and treatment response.
  • Evaluation of brain imaging and other TSC-related organ manifestations.

Main Results:

  • Most TSC infants had normal early development before spasms.
  • Hypsarrhythmia or modified hypsarrhythmia was common on initial EEGs.
  • Early diagnosis of TSC was possible in only one case (neonatal rhabdomyoma).
  • Subependymal periventricular lesions were present in all patients at IS onset.

Conclusions:

  • Preventive treatment for epileptic discharges in TSC is difficult due to diagnostic delays.
  • Early TSC diagnosis, particularly with neonatal rhabdomyoma, offers a potential window for intervention.
  • Improving early detection of TSC is essential for effective epilepsy prevention strategies.

Related Concept Videos

Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
519
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
689